JP2020511152A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511152A5
JP2020511152A5 JP2019552175A JP2019552175A JP2020511152A5 JP 2020511152 A5 JP2020511152 A5 JP 2020511152A5 JP 2019552175 A JP2019552175 A JP 2019552175A JP 2019552175 A JP2019552175 A JP 2019552175A JP 2020511152 A5 JP2020511152 A5 JP 2020511152A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019552175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511152A (ja
Filing date
Publication date
Priority claimed from DE102017106305.6A external-priority patent/DE102017106305A1/de
Application filed filed Critical
Publication of JP2020511152A publication Critical patent/JP2020511152A/ja
Publication of JP2020511152A5 publication Critical patent/JP2020511152A5/ja
Priority to JP2023044130A priority Critical patent/JP7787119B2/ja
Priority to JP2025159746A priority patent/JP2026021299A/ja
Withdrawn legal-status Critical Current

Links

JP2019552175A 2017-03-23 2018-03-23 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法 Withdrawn JP2020511152A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023044130A JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2025159746A JP2026021299A (ja) 2017-03-23 2025-09-26 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475329P 2017-03-23 2017-03-23
DE102017106305.6A DE102017106305A1 (de) 2017-03-23 2017-03-23 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017106305.6 2017-03-23
US62/475,329 2017-03-23
PCT/EP2018/057482 WO2018172533A2 (en) 2017-03-23 2018-03-23 T cell receptors and immune therapy using the same against prame positive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023044130A Division JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Publications (2)

Publication Number Publication Date
JP2020511152A JP2020511152A (ja) 2020-04-16
JP2020511152A5 true JP2020511152A5 (enExample) 2021-04-30

Family

ID=61899213

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552175A Withdrawn JP2020511152A (ja) 2017-03-23 2018-03-23 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2023044130A Active JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2025159746A Pending JP2026021299A (ja) 2017-03-23 2025-09-26 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023044130A Active JP7787119B2 (ja) 2017-03-23 2023-03-20 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法
JP2025159746A Pending JP2026021299A (ja) 2017-03-23 2025-09-26 Prame陽性がんに対するt細胞受容体およびそれを用いた免疫療法

Country Status (31)

Country Link
US (2) US11236145B2 (enExample)
EP (2) EP4450087A3 (enExample)
JP (3) JP2020511152A (enExample)
KR (2) KR20190132655A (enExample)
CN (2) CN110494160B (enExample)
AU (2) AU2018240501B2 (enExample)
BR (1) BR112019019523A2 (enExample)
CA (1) CA3056493A1 (enExample)
CL (1) CL2019002645A1 (enExample)
CO (1) CO2019011688A2 (enExample)
CR (1) CR20190482A (enExample)
DK (1) DK3600409T3 (enExample)
ES (1) ES2986840T3 (enExample)
FI (1) FI3600409T3 (enExample)
HR (1) HRP20241228T1 (enExample)
HU (1) HUE068640T2 (enExample)
IL (2) IL269578B2 (enExample)
LT (1) LT3600409T (enExample)
MA (1) MA47932B1 (enExample)
MD (1) MD3600409T2 (enExample)
MX (2) MX2019011260A (enExample)
MY (1) MY199084A (enExample)
PE (1) PE20191493A1 (enExample)
PH (1) PH12019502151A1 (enExample)
PL (1) PL3600409T3 (enExample)
PT (1) PT3600409T (enExample)
RS (1) RS65924B1 (enExample)
SG (1) SG11201908023YA (enExample)
SI (1) SI3600409T1 (enExample)
SM (1) SMT202400351T1 (enExample)
TW (1) TWI799922B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
EP3706784A4 (en) 2017-11-08 2021-12-01 BioNTech US Inc. COMPOSITIONS AND METHODS OF MANUFACTURING T-CELLS
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
PE20220763A1 (es) * 2019-05-08 2022-05-16 Janssen Biotech Inc Materiales y metodos para modular la inmunidad mediada por celulas t
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
CN115103852B (zh) * 2019-11-18 2026-01-02 德国生物新技术公司 Prame tcr受体和其用途
AU2021211485A1 (en) * 2020-01-24 2022-09-15 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof
IL295891A (en) 2020-02-24 2022-10-01 Immatics Us Inc Methods for propagating t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022017435A1 (zh) * 2020-07-22 2022-01-27 信达生物制药(苏州)有限公司 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於t細胞療法之t細胞群體的單核球耗盡
UY39967A (es) 2021-10-06 2023-05-15 Immatics Biotechnologies Gmbh Indicaciones para los aglutinantes anti-PRAME
CN113817044B (zh) * 2021-10-14 2023-10-13 深圳大学总医院 T细胞受体、相关工程化细胞及其应用
CN113789304B (zh) * 2021-10-14 2023-03-31 深圳大学总医院 高亲和力tcr及其应用
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115073584B (zh) * 2022-05-07 2023-10-20 溧阳瑅赛生物医药有限公司 一种特异性识别prame抗原肽的tcr及其应用
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
RU2578009C2 (ru) 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3268014B1 (en) 2015-03-10 2022-09-21 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
EP3297673A4 (en) 2015-05-22 2019-05-08 Memorial Sloan-Kettering Cancer Center FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES
CN106084036A (zh) 2015-11-02 2016-11-09 广州市香雪制药股份有限公司 识别prame抗原短肽的t细胞受体
CN106478809B (zh) 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr
CN106519019B (zh) 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
CN106699874B (zh) 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
CN109715669B (zh) 2016-06-17 2023-01-24 基因医疗免疫疗法股份有限公司 T细胞受体及其用途
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) * 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten

Similar Documents

Publication Publication Date Title
JP2020511152A5 (enExample)
JP2020529830A5 (enExample)
JP2020500523A5 (enExample)
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
JP2019536430A5 (enExample)
JP2023139070A5 (enExample)
CN114072427B (zh) 抗dll3嵌合抗原受体及其用途
JP2020511936A5 (enExample)
RU2017121326A (ru) Общие легкие цепи и способы их применения
JP2016505635A5 (enExample)
JP2014534242A5 (enExample)
JP2020525032A5 (enExample)
EP3294319A1 (en) T cell recruiting polypeptides based on cd3 reactivity
JP2014526898A5 (enExample)
JP2020512019A5 (enExample)
JP2016537966A5 (enExample)
JP2013538057A5 (enExample)
JP2019521641A5 (enExample)
JP2008542278A5 (enExample)
JP2012518425A5 (enExample)
JP2015504306A5 (enExample)
JP2016538830A5 (enExample)
JP2013527761A5 (enExample)
JP2018508215A5 (enExample)
JP2013532968A5 (enExample)